Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
IMGN > SEC Filings for IMGN > Form 8-K on 8-Apr-2013All Recent SEC Filings

Show all filings for IMMUNOGEN INC | Request a Trial to NEW EDGAR Online Pro



Regulation FD Disclosure


On April 7, 2013, the first clinical data were reported with BAY 94-9343 at the American Association for Cancer Research (AACR) Annual Meeting 2013 taking place in Washington, DC. BAY 94-9343 is in development by Bayer HealthCare, and utilizes ImmunoGen's Targeted Antibody Payload (TAP) technology under a license with ImmunoGen.

The data reported are initial findings from the first-in-human Phase I trial evaluating increasing doses of BAY 94-9343, administered once every three weeks, in cancer patients previously treated with other therapies. The primary objectives of the trial are to establish the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of BAY 94-9343 in this patient population.

The doses of BAY 94-9343 evaluated ranged from 0.15 mg/kg to 7.5 mg/kg, with 6.5 mg/kg established as the MTD. Forty-two patients were enrolled, including mesothelioma patients. Among these patients, one had a confirmed partial response (PR), one had an unconfirmed PR, and three patients had durable stable disease lasting at least six treatment cycles (18 weeks). These patients received BAY 94-9343 at dose levels ranging from 3.6 mg/kg to 6.5 mg/kg.

It was reported that two expansion cohorts had been opened to evaluate BAY 94-9343 when administered at its MTD - one for patients with mesothelioma and one for patients with ovarian cancer.

  Add IMGN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for IMGN - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now

Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.